Advent Pharma Ltd. announcements
129 Dhaka Stock Exchange announcements for Advent Pharma Ltd. (ADVENT) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (17).
- Emphasis of Matters
The auditor of the company has given the Emphasis of Matters paragraph in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Advent%20Pharma2025.pdf
- Credit Rating Result
Alpha Credit Rating PLC. has assigned Surveillance rating of the Company as "A-" in the long term and "ST-3" in the short term along with Stable outlook based on audited financial statements up to 30 June, 2025 and relevant qualitative information till December 08, 2025.
- Resumption after Record Date
Trading of the shares of the company will resume on 23.11.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 20.11.2025.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.15 for July-September 2025 as against Tk. 0.16 for July-September 2024; NOCFPS was Tk. 0.14 for July-September 2025 as against Tk. 0.19 for July-September 2024. NAV per share was Tk. 16.58 as on September 30, 2025 and Tk. 16.43 as on June 30, 2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.11.2025 to 19.11.2025 and trading of the shares will remain suspended on record date i.e., 20.11.2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2025 at 3:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Dividend Declaration
The Board of Directors has recommended 0.50% Cash dividend only for General Shareholders excluding Sponsors & Directors for the year ended June 30, 2025. The quantities of securities held by the said sponsors and/or directors who will not be entitled to recommended dividend: 27,957,751 shares. The amount payable to the general shareholders is Tk. 3,258,749.05. Date of AGM: 31.12.2025, Time: 12:00 PM, Venue: Hybrid System (venue details to be notified through AGM Notice). Record Date: 20.11.2025. (cont.) (Cont. news of ADVENT): The Company has also reported EPS of Tk. 0.72, NAV per share of Tk. 16.43 and NOCFPS of Tk. 1.23 for the year ended June 30, 2025 as against as against EPS of Tk. 0.90, NAV per share of Tk. 15.78 and NOCFPS of Tk. 1.88 for the year ended June 30, 2024. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (27.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 26, 2025 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Appointment of Company Secretary
The company has informed that Mr. Suman Chowdhury Barua has been appointed as the Company Secretary of the company effective from July 11, 2025.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.19 for January-March 2025 as against Tk. 0.29 for January-March 2024; EPS was Tk. 0.53 for July 2024-March 2025 as against Tk. 0.91 for July 2023-March 2024. NOCFPS was Tk. 0.89 for July 2024-March 2025 as against Tk. 1.74 for July 2023-March 2024. NAV per share was Tk. 16.24 as on March 31, 2025 and Tk. 15.78 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Category Change
The Company has been placed in 'Z' category from existing 'B' category with effect from today i.e., 10.02.2025 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Advent Pharma Limited with effect from today i.e., 10.02.2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.18 for October-December 2024 as against Tk. 0.27 for October-December 2023; EPS was Tk. 0.34 for July-December 2024 as against Tk. 0.62 for July-December 2023. NOCFPS was Tk. 0.66 for July-December 2024 as against Tk. 1.09 for July-December 2023. NAV per share was Tk. 16.06 as on December 31, 2024 and Tk. 15.78 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 2:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.